Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stemcentrx Inc.

Division of AbbVie Inc.
http://stemcentrx.com

Latest From Stemcentrx Inc.

AbbVie Puts Final Nail In Rova-T's Coffin After Another Trial Failure

AbbVie already wrote off $4bn of the $5.8bn Stemcentrx acquisition that gave it the antibody-drug-conjugate, but now the company has ended all Rova-T development.

Clinical Trials Cancer

AbbVie Will Use Allergan Revenue To Fund Combined Firm's Large R&D Pipeline

While AbbVie said its $63bn purchase places little value on Allergan's R&D pipeline, the companies have 62 drugs in clinical development with 38 in Phase II and III or filed with regulators, including new indications for approved products.

Deals Business Strategies

AbbVie’s Downward Humira Guidance Worries Analysts

Decreasing Humira’s ex-US sales guidance for the second time in three months caught significant attention, as AbbVie now expects 30% revenue erosion for its top-seller outside its home market.

Sales & Earnings Commercial

Q4 Pharma Earnings Preview: J&J, Bristol And AbbVie

Johnson & Johnson has solid growth drivers in pharmaceuticals, but still faces an overhang related to talc controversy; Bristol's call will be dominated by the just-announced Celgene acquisition; and AbbVie will face questions about its cancer plans after expensive failure with Rova-T.

Sales & Earnings Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AbbVie Inc.
  • Senior Management
  • Brian Slingerland, CEO
    Scott Dylla, PhD, CSO
  • Contact Info
  • Stemcentrx Inc.
    Phone: (650) 491-0120
    450 East Jamie Ct.
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register